Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485808 | 0.85 | TGFBR1 (0.40) | KCNH2CHRNA7IKBKBKDM5BTGFBR1 | |
| SCHEMBL486119 | 0.85 | PIK3CA (0.42) | KCNH2CHRNA7IKBKBMAP4K4 | |
| SCHEMBL486118 | 0.85 | PIK3CA (0.42) | KCNH2CHRNA7IKBKBMAP4K4 | |
| SCHEMBL485807 | 0.85 | TGFBR1 (0.40) | KCNH2CHRNA7IKBKBKDM5BTGFBR1 | |
| SCHEMBL485981 | 0.84 | MAP4K4 (0.46) | EPHX2SCN9AIKBKBMAP4K4KDM5B | |
| SCHEMBL486297 | 0.82 | NAMPT (0.41) | KCNH2CHRNA7EPHX2SCN9AIKBKB | |
| SCHEMBL486103 | 0.82 | KIT (0.48) | KCNH2EPHX2IKBKBKDRMEN1 | |
| SCHEMBL485906 | 0.82 | MEN1 (0.40) | KCNH2CHRNA7EPHX2SCN9AIKBKB | |
| SCHEMBL486210 | 0.82 | NAMPT (0.51) | KCNH2CHRNA7MEN1KMT2ATGFBR1 | |
| SCHEMBL486437 | 0.82 | TRPV1 (0.41) | KCNH2CHRNA7EPHX2SCN9AIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| EP-2411368-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109122-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109122-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | NAMPT, NNT, NQO1 | KCNH2 3403/4885CHRNA7 2813/4885EPHX2 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.